EP1526183A3
Dimer of a peptide derived from the C-terminal sequence of human superoxide dismutase facilitating the penetration of a substance into cells and/or cell nuclei
Abstract
The present invention relates to an amino acid sequence having the ability to facilitate the penetration of a substance of interest into cells and / or cell nuclei, characterized in that said sequence has less than 25 acids amino and consists of a dimer of a peptide derived from the C-terminal portion of the sequence of human superoxide dismutase capable of reacting in vivo with heparin-like aminoglycans, chondroitin sulfates and their derivatives.
Term
Term ended
Projected expiry passed 1 March 2021, 5.6 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both waysCites: the store holds 4 of 5
| Document | Relation | Office | Category | Cited during | Relevant claims |
|---|---|---|---|---|---|
| WO9104315A1 | Cites | World Intellectual Property Organization (WIPO) | A | Search report | 1-47 |
| WO9608274A2 | Cites | World Intellectual Property Organization (WIPO) | XY | Search report | 1-4,6,8,11-13,24-33,37-47 |
| WO9856938A1 | Cites | World Intellectual Property Organization (WIPO) | XY | Search report | 1-4,6,8,11-13,24,25,30-33,37-47 |
| WO9907414A1 | Cites | World Intellectual Property Organization (WIPO) | DY | Search report | 14-23,26-29,34-36 |
56 members in 16 offices
Priority claims9
| Document | Office | Kind | Date |
|---|---|---|---|
| 0002621 | France | A | |
| 0002621 | France | A | |
| 0002621 | France | – | |
| 01911821 | European Patent Office (EPO) | A | |
| 01911821 | European Patent Office (EPO) | A | |
| 0002621 | – | – | – |
| 01911821 | – | – | – |
| EP20010911821 | – | – | – |
| FR20000002621 | – | – | – |
Members56
| Document | Office | Kind | |
|---|---|---|---|
| CA2401613A1 | Canada | A1 | |
| FR2805821A1 | France | A1 | |
| WO0164738A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU4074801A | Australia | A | |
| WO0164738A3 | World Intellectual Property Organization (WIPO) | A3 | |
| EP1259541A2 | European Patent Office (EPO) | A2 | |
| BR0108847A | Brazil | A | |
| CA2458866A1 | Canada | A1 | |
| WO03018636A2 | World Intellectual Property Organization (WIPO) | A2 | |
| IL151399A0 | Israel | A0 | |
| IL151399D0 | Israel | D0 | |
| US2003153490A1 | United States of America | A1 | |
| JP2003528596A | Japan | A | |
| US2003199677A1 | United States of America | A1 | |
| WO03018636A3 | World Intellectual Property Organization (WIPO) | A3 | |
| FR2805821B1 | France | B1 | |
| EP1427758A2 | European Patent Office (EPO) | A2 | |
| IL160319A0 | Israel | A0 | |
| IL160319D0 | Israel | D0 | |
| BR0212203A | Brazil | A | |
| CN1549826A | China | A | |
| JP2005505266A | Japan | A | |
| AU780785B2 | Australia | B2 | |
| EP1526183A2 | European Patent Office (EPO) | A2 | |
| NZ531101A | New Zealand | A | |
| AU2005201938A1 | Australia | A1 | |
| EP1526183A3This record | European Patent Office (EPO) | A3 | |
| US7049286B2 | United States of America | B2 | |
| US2006166889A1 | United States of America | A1 | |
| US7112562B2 | United States of America | B2 | |
| EP1259541B1 | European Patent Office (EPO) | B1 | |
| AT372346T | Austria | T | |
| ATE372346T1 | Austria | T1 | |
| EP1427758B1 | European Patent Office (EPO) | B1 | |
| DE60130324D1 | Germany | D1 | |
| AT375999T | Austria | T | |
| ATE375999T1 | Austria | T1 | |
| DE60223058D1 | Germany | D1 | |
| PT1259541E | Portugal | E | |
| DK1259541T3 | Denmark | T3 | |
| PT1427758E | Portugal | E | |
| DK1427758T3 | Denmark | T3 | |
| ES2292567T3 | Spain | T3 | |
| ES2294195T3 | Spain | T3 | |
| DE60130324T2 | Germany | T2 | |
| DE60223058T2 | Germany | T2 | |
| IL190542A0 | Israel | A0 | |
| IL190542D0 | Israel | D0 | |
| JP2008271970A | Japan | A | |
| IL151399A | Israel | A | |
| EP1526183B1 | European Patent Office (EPO) | B1 | |
| AT423849T | Austria | T | |
| ATE423849T1 | Austria | T1 | |
| DE60137801D1 | Germany | D1 | |
| US8003595B2 | United States of America | B2 | |
| JP4912556B2 | Japan | B2 |
48 legal events, as 5 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Notification of lapseLapsedST | ST | FR | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Be: lapsedLapsedBERE | BERE | EP | |
| European patents designating ireland treated as always having been voidFD4D | FD4D | IE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents actLapsedNLV1 | NLV1 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Corresponds to:REF | REF | EP | |
| European patents granted designating irelandGrantedLANGUAGE OF EP DOCUMENT: FRENCHFG4D | FG4D | IE | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Divisional application: reference to earlier applicationAC | AC | EP | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedNOT ENGLISHFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Designation fees paidAKX | AKX | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Information on inventor provided before grant (corrected)RIN1 | RIN1 | EP | |
| Request for examination filed17P | 17P | EP | |
| Divisional application: reference to earlier applicationAC | AC | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 1526183
- Publication, DOCDB
- 1526183
- Publication, EPODOC
- EP1526183
- Application
- 4292771
- Application, DOCDB
- 04292771
- Application, EPODOC
- EP20040292771
Titles3
- German
- Dimer eines aus der C-terminalen Sequenz der humanen Superoxid Dismutase abgeleiteten Peptids, welches das Eindringen einer Substanz in Zellen und/oder Zellkerne erleichert
- English
- Dimer of a peptide derived from the C-terminal sequence of human superoxide dismutase facilitating the penetration of a substance into cells and/or cell nuclei
- French
- Dimère d'un peptide dérivé de la partie C-terminale de la séquence de superoxyde dismutase humaine facilitant la pénétration d'une substance à l'intérieur des cellules et/ou des noyaux cellulaires
Classification
- CPC, 23
- C07K7/06
- A61K38/00
- A61K47/42
- A61K47/64
- A61K48/00
- A61K47/6811
- A61K47/6835
- C07K7/08
- C07K14/62
- A61P9/10
- C07K16/32
- A61P31/00
- C07K16/40
- A61P31/04
- C07K16/4283
- A61P31/12
- C07K16/44
- A61P35/00
- C07K17/14
- C07K2317/54
- C07K2317/565
- C12N9/0089
- C12N15/87
- IPC, 31
- A61K38 00
- A61K39 395
- A61K47 42
- A61K47 48
- A61K48 00
- A61P9 10
- A61P31 04
- A61P31 12
- C12N15 09
- A61P35 00
- C07K5 11
- C07K7 04
- C07K7 06
- C07K7 08
- C07K14 00
- C07K14 47
- C07K14 62
- C07K16 18
- C07K16 32
- C07K16 40
- C07K16 42
- C07K16 44
- C07K17 14
- C07K19 00
- C12N1 14
- C12N1 15
- C12N1 19
- C12N5 00
- C12N5 10
- C12N9 02
- C12N15 87
Designated states20
- Contracting states, 20
- Austria
- Belgium
- Switzerland
- Cyprus
- Germany
- Denmark
- Spain
- Finland
- France
- United Kingdom
- Greece
- Ireland
- Italy
- Liechtenstein
- Luxembourg
- Monaco
- Netherlands (Kingdom of the)
- Portugal
- Sweden
- Türkiye